Explore licensed vaccines, adverse event reporting data, and history for this disease.
- Phase 1
- Phase 2
- Phase 3
- Filed
- Approved
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Not Filed / Pre-submission |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Stage known from the trial registry only; no jurisdiction-specific filing date.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Current position: Phase 2
| Jurisdiction | Status in the record | Submission | Regulator decision | Earliest routine use |
|---|---|---|---|---|
| United StatesFDA (CBER) · ACIP (CDC) | no jurisdiction-specific filing known | 2029-102028-01 to 2033-01 | 2030-082028-07 to 2034-04 | 2030-112028-07 to 2034-12 |
| European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others) | no jurisdiction-specific filing known | 2029-102028-01 to 2033-01 | 2030-122028-10 to 2034-09 | 2031-062028-11 to 2036-03 |
| CanadaHealth Canada · NACI | no jurisdiction-specific filing known | 2029-102028-01 to 2033-01 | 2030-082028-07 to 2034-04 | 2030-122028-08 to 2035-04 |
| United KingdomMHRA · JCVI | no jurisdiction-specific filing known | The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used. | ||
| AustraliaTGA · ATAGI | no jurisdiction-specific filing known | TGA registration-timeframe pages timed out on 2026-10-24; no target is used. | ||
| JapanPMDA / MHLW · MHLW immunisation subcommittee | no jurisdiction-specific filing known | PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure. | ||
| WHO prequalificationWHO Prequalification · SAGE | no jurisdiction-specific filing known | WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used. | ||
Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.
Scientific Profile & Documentation
- Platform Architecture
- Biological (unspecified platform)
- Lead Developer
- AstraZeneca
- Next Expected Milestone
- Primary completion (most advanced trial): 2026-10-01 (registry estimate)
- Analyst & Development Notes
- Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
- Primary Source Documentation
- ClinicalTrials.gov NCT07717840 →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
Milestone Overview
-
Stage VerificationPhase 2 Clinical Trial confirmed as of 2026-10-30.
-
Target MilestonePrimary completion (most advanced trial): 2026-10-01 (registry estimate)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.